OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


Weekly Carboplatin Plus Paclitaxel Improves Quality of Life

(March 14, 2014)  A large European clinical trial showed that carboplatin plus paclitaxel once a week (versus every three weeks) can be an effective front-line treatment for women with advanced ovarian cancer. The results of the study were published in the medical journal The Lancet.

Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule combined with carboplatin every 3 weeks prolonged progression-free survival and overall survival in a Japanese phase 3 trial. The aim of this study, which enrolled over 800 women, was to assess whether a weekly schedule of carboplatin plus paclitaxel is more effective than the same drugs given every 3 weeks.

Researchers found that the weekly regimen increased progression free survival from a median of 17.3 months to 18.3 months. Significantly, quality of life, as measure by the FACT-O/TOI scoring system, was different as well. With treatment every 3 weeks, FACT-O/TOI scores worsened at every cycle, whereas for the weekly schedule, after transient worsening at week 1, FACT-O/TOI scores remained stable.

The researchers conclude that a weekly schedule of carboplatin plus paclitaxel is effective and may also offer better quality of life for patients.

Click here for the abstract.